

ASX ANNOUNCEMENT

ADMEDUS AWARDED MAJOR SUPPLY TENDER

- Admedus awarded major supply contract for infusion product range
- Provides significant revenue boost to Company sales going forward
- Admedus infusion team focuses on bringing hospital wide healthcare solutions

Brisbane, Australia 25th May 2016

Admedus today announced that it has been awarded a major supply contract for the new Royal Adelaide Hospital (new RAH) for the installation of the arcomed Chroma Infusion pump system. The new RAH is an 800 bed hospital which will provide world class healthcare and facilities for South Australians.

Manufactured by arcomed ag the Swiss made Chroma Infusion pumps offer an innovative whole-of-hospital system with smart pump technology. The LCD touch screen, drug error reduction system and colour coding of medications on the screen increase patient safety and enhance clinical workflow.

The supply tender includes ongoing technical and clinical support and dedicated consumable products for use with the infusion systems over the coming 5 years.

Mr Wayne Paterson, Admedus Chairman and interim Managing Director commented: "We are encouraged by the uptake of arcomed Chroma Infusion pump systems within Australia which confirms both the quality and value to the health care system of the product range. As outlined in the recent quarterly report, the Admedus team remains focused on providing hospital-wide infusion solutions across the Australian and New Zealand healthcare systems."

Mr Beat Rechsteiner, Director Global Business for arcomed ag, commented "arcomed is proud to partner with the new Royal Adelaide Hospital and Admedus to bring the latest innovations in infusion technology to the State's flagship hospital. The decision from the new RAH confirms that arcomed is delivering the infusion technology hospitals today need to help them achieve their goals of patient safety, convenience and cost effectiveness."

Admedus has one of the largest infusion product ranges on market in Australia and New Zealand, demonstrating the Company's ability to provide complex infusion solutions across hospitals and healthcare services groups.

Follow us:

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus

Website: www.admedus.com

Blog: www.admedus.com/au/category/news/

For more information, please contact:

Dr Julian Chick | Chief Operating Officer | Admedus Limited

Tel: +61 (0)8 9266 0100

Media:

Shevaun Cooper | PR Manager | Admedus Limited

Tel: +61 (0) 417 985 599 | Email: scooper@admedus.com

Media Europe

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0) 20 3727 1000

admedus@fticonsulting.com

US Investor

Rx Communications Group, LLC

Melody A. Carey

+1 917 322 2571

mcarey@rxir.com

About Admedus Limited

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on www.admedus.com